Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted therapy + adjuvant chemotherapy in stage T3-4N2 colorectal cancer
NCT05797467Phase 3Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Apr 2023
- Primary completion
- Apr 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, KL-140 in colorectal cancer (CRC), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Started Apr 2023; status: recruiting.
02
Drugs
bevacizumabKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05797467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797467.